Reply to “Foregoing Nonclinical Dosimetry Studies to Support First-in-Human Studies of Certain PET Radiopharmaceuticals.” ow.ly/jB9250WoMes #Nuclearmedicine #PETscan #Dosimetry ScottLab Coalition of PET Drug Manufacturers Sally Schwarz Marianna Dakanali FDA

3/5 - Standard imaging underperforms in ILC - Better tools are needed • FES PET tracks ER • FAPI, PSMA, and fluciclovine PET are promising • WB-DWI/MRI ⬆️ sensit. for bone/peritoneal mets • ctDNA may help—but needs validation in ILC Innovation is there, we need data in ILC

Proud to share our new nature study: We developed the 1st NNMT inhibitor that reprograms cancer-associated fibroblasts, boosting immune response & stopping tumor growth in ovarian cancer models, especially when paired with immunotherapy. Lengyel Lab nature.com/articles/s4158…

DG04 officially published NEJM ASCO. This comes 10 years after my first phase 1 patient. DG04 took 3.5+ years due to <15% HER2+ and fresh biopsy to confirm HER2. Grateful for global effort—hoping this expands T-DXd access worldwide nejm.org/doi/full/10.10… OncoAlert OncoDaily

The NRG Oncology ADC Summer symposium kicks off with two amazing talks by Drs. Pat LoRusso and Ian Krop, reviewing the history and potential way forward for ADCs in solid tumors. The hope: to replace each like of chemo with an ADC. The need, to get there: payload differentiation!

Lessons learned with ADCs for GI tumors, presented by Michael Cecchini Yale University. Notable example in gastric cancer: ADCs with topo1 payloads are more effective than small molecule topo1 inhibitors! (DG01). A lot more happening beyond HER2, eg multiple promising Claudin ADCs emerging.

Extremely important lessons on ADCs learned through testing in GI tumors. Michael Cecchini NRG Oncology

Lessons learned with the use of ADCs in thoracic oncology. Biagio Ricciuti, MD, PhD Dana-Farber

What “fancy” ADCs are in the pipeline? Rafeh Naqash, MD reviews the rapidly evolving field of ISACs, DACs, bsADCs and further innovative ways of utilizing the ADC paradigm to selectively deliver anticancer molecules to tumors. Many bumps along the way, a lot of hopes for the future

Terrific closing for the NRG Oncology ADC symposium, with Lauren Price from the U.S. FDA highlighting the evolution of dose-optimization strategies for ADCs. Lots of work ongoing to identify the RIGHT dose of ADC treatments as EARLY as possible during development.

Thanks DrKatyMoore Paolo Tarantino for organizing such a state of the art session on everything about ADCs across solid tumors and the invite to talk about ADCs in GU cancers! What an incredible session with an all ⭐️ faculty with the best part being the realistic and poignant

Excited to share our latest publication from the EN-SEMBLE study in ESMO Open! ESMO Open Post-T-DXd therapy is a major unmet need in HER2+ mBC. This large, real-world study provides insights into treatment patterns, outcomes, and the risk of ILD. 👉 doi.org/10.1016/j.esmo…

Finally, a killer application for Y-90 FAPI theranostics? Near complete metabolic responses in 3 patients with treatment refractory solitary fibrous tumors. Ga-68 FAPI had high SUVs (117, 41, 31) with concordant FDG uptake. jnm.snmjournals.org/content/early/… SNMMI Wonderful work from

VC deployment by therapeutic areas [2023-2025 YTD] Source: Evercore

Ph1 data from a new CEACAM5 topo1 ADC (Precemtabart tocentecan 😵‍💫) in mCRC (n=40). Modest activity (ORR 7.5%), maybe due to cross-resistance with prior irinotecan. Several DLTs, including G5 sepsis in an obese pt. Important to cap ADC doses in these pts! nature.com/articles/s4159…

We've known that Covid increases the risk in survivors of cancer, but today nature a mechanism of reactivation of cancer cells elucidated in the experimental model nature.com/articles/s4158… nature.com/articles/d4158…

A new PET biomarker in men with high-risk metastatic castration-resistant prostate cancer. Total tumor volume prognostic for overall survival and predictive for benefit of Lu-177 PSMA-617. Great data from ANZUP ENZA-P led by Louise Emmett authors.elsevier.com/c/1lWie5EIIgTS9~

Access the full paper on PSMA-PET prognostic and predictive biomarkers in ENZAp with the link below: ANZUP LancetOncology NHMRC CTC Movember Australia Prostate Cancer Foundation authors.elsevier.com/a/1lWie5EIIgTS…

🚨Online today: Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant #prostatecancer in #ENZAp (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial thelancet.com/journals/lanon…

Translating Discovery into Impact | Journal of Nuclear Medicine jnm.snmjournals.org/content/66/8/1…